BioXyTran Inc.’s drug BXT-252 is designed to treat chronic wounds resulting from ischemia caused by occlusion of capillaries. BXT-252 has the same modality and physical properties as BXT-25; however, its proprietary co-polymer can improve the healing of pressure and arterial ulcers. BXT-252 is also a modified hemoglobin structure. Its size, roughly 1/5,000th that of a red blood cell, enables it to perfuse constricted, ischemic capillaries, which are inaccessible to red blood cells due to ischemia conditions or other obstructions of the blood flow.